Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine

NCT03497572 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 145

Last updated 2018-05-08

No results posted yet for this study

Summary

The study aims to assess antibody persistence induced by Spirolept® vaccination in subjects who received at least 4 doses (2 doses two weeks apart and 2 booster doses) and no more than a total of 8 doses (2 doses two weeks apart and 6 booster doses).

Conditions

  • Leptospirosis

Sponsors & Collaborators

  • Imaxio

    lead INDUSTRY

Principal Investigators

  • Maryse Beder, MD · SIAAP

  • Simonetta Viviani, MD · Imaxio

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-25
Primary Completion
2018-04-12
Completion
2018-04-12

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497572 on ClinicalTrials.gov